in the FY 2007 and 2008 U.S. Congressional Appropriations budgets for
the Department of Defense.
-- Presenting new mechanistic data for Valortim(TM) showing that
Valortim(TM) may possess the ability to enhance macrophage killing of
Bacillus anthracis (anthrax) spores within macrophages, potentially
blocking the ability of the spores to develop into bacteria and
preventing toxin production and propagation of the infection.
-- Demonstrating new research showing that recombinant
butyrylcholinesterase (rBChE) may effectively block the formation of
amyloid fibrils, which are believed to be important precursors to
-- Showing a therapeutic effect for Valortim(TM) in a new primate model of
established inhalation anthrax infection -- the African Green Monkey
model, which is believed to follow a similar disease course as would be
expected in humans exposed to aerosolized Bacillus anthracis (anthrax)
spores. The pilot study demonstrated 50% survival in Valortim(TM)-
treated animals compared to no animals in the control group; this was
perceived to be an encouraging survival result since the study animals
had bacteria multiplying in their blood and were poised to manifest
severe symptoms and death at the time they received treatment.
For the year ended December 31, 2007, PharmAthene recognized revenues of $14.6 million compared to $1.7 million for the period ended December 31, 2006. The Company's revenues consist primarily of contract and grant funding from the U.S. government. The increase in revenue in 2007 is primarily attributable to revenues of $14.6 million provided under the Department of Defense advanced development and procurement contract for Protexia(R), which was executed in September 2006.
PharmAthene's research and developmen
|SOURCE PharmAthene, Inc.|
Copyright©2008 PR Newswire.
All rights reserved